Yayınlar & Eserler

Yayın Ağı
Makaleler 13
Tümü (13)
SCI-E, SSCI, AHCI (9)
SCI-E, SSCI, AHCI, ESCI (12)
ESCI (3)
Scopus (13)
TRDizin (2)

1. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.
Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded, Scopus)

2. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Kahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., et al.
BMC Cancer , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

3. The knockdown of stathmin with si-RNA inhibits invasion of mesothelioma

AKSOY A., Varoglu A., Onalan E. E., Tektemur A., Artas G., Koc M., et al.
Tissue and Cell , cilt.87, 2024 (SCI-Expanded, Scopus)

4. The evaluation of cyclin D1 expression in prostate carcinoma cases Prostat kanseri hastalarında siklin D1 ekspresyonunun değerlendirilmesi

AKSOY A., Vicdanli S., Artas G.
Northern Clinics of Istanbul , cilt.11, sa.6, ss.534-540, 2024 (ESCI, Scopus, TRDizin) Creative Commons License

5. Covid-19-induced cavernous sinus thrombosis in a myelodysplastic syndrome patient: case report

Orhan Varoglu A., AKSOY A., Akbas E., Atalay B.
Egyptian Journal of Neurology, Psychiatry and Neurosurgery , cilt.59, sa.1, 2023 (ESCI, Scopus)

6. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atcı M. M., Kahraman S., Kılıçkap S., et al.
Journal of Cancer Research and Clinical Oncology , cilt.149, sa.8, ss.4141-4148, 2023 (SCI-Expanded, Scopus)

7. Reversible Severe Parkinsonism Caused by Extra-Pontine Myelinolysis in a patient with Primary Adrenal Failure

Orhan Varoglu A., AKSOY A., Avarisli A., Darici D., Akbas E.
Neuro endocrinology letters , cilt.44, sa.2, ss.97-100, 2023 (SCI-Expanded, Scopus)

8. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., BAYRAM E., Demirel B. C., et al.
Future Oncology , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)

9. The overexpression of cyclin D1 is a positive prognostic factor in advanced-stage breast carcinoma cases

AKSOY A., Sevim M., Artas G.
Northern Clinics of Istanbul , cilt.10, sa.6, ss.726-733, 2023 (ESCI, Scopus, TRDizin)

10. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Hizal M., Bilgin B., Paksoy N., Klllçkap S., Atcl M. M., Kahraman S., et al.
Future Oncology , cilt.18, sa.23, ss.2573-2582, 2022 (SCI-Expanded, Scopus)

11. Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study

Yasin A. I., AYDIN S., SÜMBÜL B., KORAL L., Simşek M., Geredeli Ç., et al.
Future Oncology , cilt.18, sa.10, ss.1235-1244, 2022 (SCI-Expanded, Scopus)

12. Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma: A Multicentric Study

YILMAZ Ş., YILMAZ DEMİRCİ N., METİNTAŞ S., Zamani A., Karadag M., AYDIN GÜÇLÜ Ö., et al.
Journal of Occupational and Environmental Medicine , cilt.63, sa.3, ss.238-243, 2021 (SCI-Expanded, Scopus)

13. Serum uric acid levels in patients with relapsing-remitting multiple sclerosis

ALTINKAYNAK K., Varoǧlu A. O., Aksoy H., Deniz O., AKSOY A.
European Journal of General Medicine , cilt.6, sa.3, ss.166-169, 2009 (Scopus)
Metrikler

Yayın

13

Yayın (WoS)

12

Yayın (Scopus)

13

H-İndeks (WoS)

4

Atıf (Scopus)

81

H-İndeks (Scopus)

4

Proje

1

Tez Danışmanlığı

5

Açık Erişim

1
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER